• If you are wondering whether DaVita at around US$151.65 is still priced reasonably or already baking in a lot of optimism, the next sections will help you frame that question clearly.
• The stock's recent performance has been mixed in the short term, with a 0.1% decline over 7 days, a 4.2% gain over 30 days, and longer term returns of 32.4% year to date, 7.5% over 1 year, 71.4% over 3 years, and 19.6% over 5 years.
• Recent coverage has focused on DaVita's role in the US healthcare system and ongoing attention on dialysis providers, with investors watching how policy and regulatory discussions could affect large players in the sector. There has also been interest in how capital allocation decisions and balance sheet management might shape the stock's risk and reward profile.
• Simply Wall St currently gives DaVita a valuation score of 5/6, suggesting that on several checks the shares look cheaper than some fundamental metrics imply. The rest of this article will compare different valuation approaches before ending with a more holistic way to think about what the stock might be worth.

Approach 1: DaVita Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth by projecting its future cash flows and then discounting those cash flows back to today using a required rate of return.

For DaVita, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $1,285.9 million. Simply Wall St uses analyst inputs where available, then extrapolates beyond that. For example, Free Cash Flow for 2026 is set at $1,244 million, and by 2035 the extrapolated Free Cash Flow in the model is $1,459.9 million, with each of the years in between stepping through relatively small changes rather than dramatic swings.

After discounting these projected cash flows, the DCF model arrives at an estimated intrinsic value of about $390.30 per share. Compared with the recent share price around $151.65, this framework suggests the stock trades at roughly a 61.1% discount to that intrinsic estimate. On this metric alone, the shares appear materially undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests DaVita is undervalued by 61.1%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: DaVita Price vs Earnings

For profitable companies, the P/E ratio is a useful shorthand because it connects what you pay for each share with the earnings that each share currently generates. Investors often use it to get a quick sense of how the market is pricing those earnings.

What counts as a “normal” or “fair” P/E depends on how the market views a company’s growth prospects and risk. Higher expected growth or lower perceived risk often justify a higher P/E, while slower growth or higher risk usually point to a lower P/E.

DaVita currently trades on a P/E of 13.85x. That sits well below the Healthcare industry average of about 24.86x and also below the peer group average of 41.52x. Simply Wall St also provides a “Fair Ratio” of 22.50x, which is an estimate of the P/E that might be appropriate given factors such as DaVita’s earnings growth profile, margins, industry, market cap and risk characteristics.

This Fair Ratio can be more informative than a simple comparison with industry or peers because it adjusts for company specific drivers rather than assuming all Healthcare stocks deserve the same multiple. Compared with DaVita’s current 13.85x P/E, the Fair Ratio of 22.50x indicates the shares may be trading below what those fundamentals imply.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.

Upgrade Your Decision Making: Choose your DaVita Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives take the DCF and P/E style numbers you have just seen and ask you to attach a clear story to them by spelling out what you think happens to DaVita’s future revenue, earnings and margins. They link that story to a forecast and then to a Fair Value that you can compare with the current price on Simply Wall St’s Community page, where Narratives are available to millions of users and refresh automatically when new information such as earnings or news arrives. For DaVita, one investor might lean toward a higher Fair Value closer to the bullish analyst view around US$179.66 per share because they focus on technology, Integrated Kidney Care and margin expansion. Another might anchor nearer the bearish US$126.00 view because they put more weight on reimbursement pressure, volume risk and slower margin progress. Seeing those different Narratives side by side can help you decide whether the current price of about US$151.65 fits your own expectations or calls for patience.

For DaVita however we will make it really easy for you with previews of two leading DaVita Narratives:

Each one lines up the same share price with very different assumptions about revenue, margins and the P/E investors might be willing to pay a few years from now. Use them as a shortcut to check which story feels closer to how you see the business.

Fair value in this bullish narrative: US$151.71 per share

Gap to that fair value versus the recent price of US$151.65: roughly flat, at about 0.0% undervalued using the narrative inputs

Revenue growth assumption: 3.55% a year

• Focuses on steady demand for dialysis, cost control, and clinical improvements that support margins while patient volumes and treatment mix evolve.
• Builds in modest revenue and margin improvements, a lower future P/E of about 11x, and a shrinking share count from buybacks to reach the 2029 earnings targets used in the model.
• Flags real risks around mortality, reimbursement levels and ancillary revenues, and encourages you to test whether those assumptions feel realistic before accepting the fair value.

Fair value in this bearish narrative: US$126.00 per share

Gap to that fair value versus the recent price of US$151.65: about 20.4% overvalued on these assumptions

Revenue growth assumption: 4.76% a year

• Highlights higher near term costs from IT and AI projects, pressure on treatment volumes and payer mix, and uncertainty around value based care earnings.
• Assumes revenue growth of about 4.8% a year but a margin step down to roughly 5.2%, alongside a future P/E of around 11x and continued buybacks, to arrive at the lower fair value.
• Points to volume, payer mix and IKC profitability as key swing factors that could either support or weaken this cautious view if they evolve differently from the current assumptions.

If you want to go beyond the previews and see how other investors are connecting these numbers to long term stories for DaVita, it is worth spending a few minutes with the full set of community narratives and valuation tools on Simply Wall St, including the To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for DaVita on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for DaVita? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.